Nick Schopman PhD

European patent attorney, Dutch patent attorney, Belgian patent attorney

Nick Schopman

Biotechnology, microbiology, virology, immunology, medical technology, biochemistry, gene therapy, immunotherapy, chemical technology, agrifood

Before he started working at Arnold & Siedsma, Nick was employed as a consultant at a grants consultancy firm where he provided advice and assistance to companies who applied for (national and European) tax and grant schemes for technological innovation projects. A crucial element in that respect is intellectual property protection.

After his Biotechnology studies at Wageningen University, Nick subsequently obtained his doctorate from Amsterdam University with a thesis on the development of gene therapy to combat HIV-1 based on RNA interference.  He carried out his doctoral research at Amsterdam Medical Centre. During this period he gained ample research experience in the field of new antiviral strategies and therapeutic small molecules such as antivirals, small RNAs, vaccines, synthesised albumin, antibodies and biomarkers. His affinity with intellectual property grew during this period, where the promotional research was a follow-up of two patent applications.

Others about Nick:
Analytical, inquisitive, result driven, a go-getter and disciplined

Professional experience:
2018 - present: Patent attorney at Arnold & Siedsma
2015 - 2018: Trainee patent attorney at Arnold & Siedsma
2012 - 2015: Sr. consultant at SUBtracers

2008 - 2012: University of Amsterdam, PhD medicine
2002 - 2007: Wageningen University, MSc biotechnology

Dutch and English

Dicer-independent processing of short hairpin RNAs. Liu YP, Schopman NC, Berkhout B. Nucleic Acids Res. 2013 Feb 1.

Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. van der Sluis RM, van Montfort T, Centlivre M, SchopmanNC, Cornelissen M, Sanders RW, Berkhout B, Jeeninga RE, Paxton WA, Pollakis G. J Virol Methods. 2012 Oct 8.

Selective packaging of cellular miRNAs in HIV-1 particles. Schopman NC, van Montfort T, Willemsen M, Knoepfel SA, Pollakis G, van Kampen A, Sanders RW, Haasnoot J, Berkhout B. Virus Res. 2012 Jun 21.

Theses, Nick Schopman, Interplay between the RNA interference machinery and HIV-1, 24 Feb 2012

Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs. Schopman NC, Braun A, Berkhout B. Antimicrob Agents Chemother. 2012 Jan;56(1):479-86. Epub 2011 Nov 7.

Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs.Schopman NC, Willemsen M, Liu YP, Bradley T, van Kampen A, Baas F, Berkhout B, Haasnoot J. Nucleic Acids Res. 2011 Sep 12.

A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. Schopman NC, Heynen S, Haasnoot J, Berkhout B. RNA Biol. 2010 Sep 23;7(5).

Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs.Schopman NC, ter Brake O, Berkhout B. Retrovirology. 2010 Jun 8;7:52.

Optimization of shRNA inhibitors by variation of the terminal loop sequence.Schopman NC, Liu YP, Konstantinova P, ter Brake O, Berkhout B. Antiviral Res. 2010 May;86(2):204-11.

Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Liu YP, von Eije KJ, Schopman NC, Westerink JT, Brake O, Haasnoot J, Berkhout B.Mol Ther. 2009 Oct;17(10):1712-23.

Inhibition of Henipavirus infection by RNA interference. Mungall BA,Schopman NC, Lambeth LS,Doran TJ. Antiviral Res. 2008 Dec;80(3):324-31.

Expression of the polymeric Immunoglobulin Receptor (pIgR) in mucosal tissues of common carp (Cyprinus carpio L.). Rombout JH, van der Tuin SJ, Yang G, Schopman N, Mroczek A, Hermsen T, Taverne-Thiele JJ. Fish Shellfish Immunol. 2008 May;24(5):620-8.

Telephone: +31 70 3654833